Innovotech Inc., a Canadian biotechnology company currently listed on the TSX Venture Exchange under the symbol IOT, has announced its intention to apply for a stock quotation on the OTCQB Venture Market in the United States. This strategic move is designed to enhance the company's profile within the U.S. investment community and make its shares more accessible to American retail and institutional investors. The primary objective is to increase trading liquidity for the company's common shares.
The OTCQB quotation would operate alongside Innovotech's existing Canadian listing, with the company expecting no significant additional compliance or reporting burdens. As a foreign private issuer, Innovotech will continue to meet its disclosure obligations through the Canadian SEDAR+ system, which satisfies OTC market requirements under established exemptions for foreign companies. Admission to the OTCQB requires companies to meet specific financial standards, maintain current reporting, and complete an annual verification and management certification process.
In conjunction with the OTCQB application, Innovotech will also seek eligibility with the Depository Trust Company (DTC). This step is crucial as it would enable simplified electronic clearing and settlement of the company's common shares for investors based in the United States, streamlining the trading process. Innovotech Inc. is a boutique contract research organization specializing in advanced laboratory services and proprietary technology commercialization. The company is recognized as a leader in biofilm science, providing expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions.
Innovotech's services are supported by innovative methodologies and products, including its widely-used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. The company serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards, such as those enforced by the U.S. Food and Drug Administration and Health Canada. These operations are conducted through its ISO-certified and GMP-accredited laboratories. More information about the company's work is available at https://www.innovotech.ca.
This announcement is significant as it represents a strategic effort by a specialized Canadian life sciences firm to tap into the larger and more liquid U.S. capital markets. For investors, particularly those in the United States, it provides potential access to a company operating in the critical field of antimicrobial resistance and biofilm science—areas of growing global health importance. Increased visibility and liquidity could lead to more efficient price discovery and potentially attract a broader base of investment. For the biotechnology industry, it highlights the ongoing cross-border integration of capital markets, allowing specialized firms to seek funding beyond their domestic exchanges. The company's forward-looking statements note that actual results may differ due to various risks, including regulatory changes, currency fluctuations, reliance on key customers, and intellectual property uncertainties. The original release can be viewed on http://www.newmediawire.com.
